GSK plc (LSE/NYSE: GSK) and Alfasigma S.p.A. today announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor being developed for cholestatic pruritus in primary biliary cholangitis (PBC).
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, and Innovative Molecules GmbH (“Innovative Molecules”), a clinical-stage biotechnology company, today announced a strategic partnership whereby Alfasigma will invest in Innovative Molecules and has obtained the exclusive worldwide license to the parenteral formulation of adibelivir (formerly IM 250) for the treatment of Herpes Simplex Virus (HSV) encephalitis, an ultra-rare and life threatening condition.
Alfasigma has taken another step in its transformation journey by adopting an Open Access publication policy, ensuring that all company-sponsored and funded research is accessible barrier-free to everyone, for the benefit of health care professionals, patients, caregivers, and the global scientific community.
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, IBD (Inflammatory Bowel Disease), gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis), Ulcerative Colitis, PBC (Primary Biliary Cholangitis)
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies are the main pathologies in which we offer solutions
We provide treatments to relieve symptoms and signs in patients affected by rheumatoid arthritis
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue
Alfasigma's business strategy is closely linked to the principles of sustainability. We support scientific popularization and play a proactive role in the areas of culture, art, and civil society. We recognize that a pharmaceutical company is also a cultural entity. The dignity of a person is not only about being healthy, but encompasses all aspects of life and the environment in which they live, reflecting an idea of the overall well-being of society.
You’re entering Alfasigma global website
I agree